Lyra Therapeutics Inc at Stifel Healthcare Conference Transcript
The Lyra Therapeutics presentation. I'm Annabel Samimy, biopharmaceutical analyst at Stifel -- I almost forgot where I work. And we have Maria Palasis, the CEO of Lyra, who will introduce the company who is solving a matrix for refractory sinusitis. So, why don't you come join us, give the presentation, and we'll go from there.
Thank you, Annabel. It's a pleasure to be here, and I'm excited to speak about the progress that the company is making. We believe that Lyra is in a really strong position to be able to transform how chronic rhinosinusitis is being treated. It is a disease that just has an enormous un-met need.
We're actually really proud to be one of the few companies that's focused on chronic rhinosinusitis. It's a population in the US of about 14 million patients that have this disease. And unfortunately, there's not a drug that's approved to treat these patients. It's a global problem -- not just in the US, but throughout the world, with millions
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |